Improved understanding of Waldenström’s macroglobulinemia (WM) and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy, Meletios Dimopoulos, MD, said at the 2016 Society of Hematologic Oncology annual… Continue reading →
Through a partnership with the American Association for Clinical Chemistry (AACC), the IWMF has added a terrific new resource to our web site–to help WM patients and caregivers better understand laboratory results…please see http://www.iwmf.com/about-wm/blood-tests.
Waldenström Macroglobulinemia: biology, genetics, and therapy
Author(s): Paludo J, Ansell SM
Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon… Continue reading →
The Waldenstrom’s Macroglobulinemia Foundation of Canada would like to extend a sincere thank you to Bert Visheau, a Board of Director member since 2003, for his dedication and support to the WMFC. Bert has stepped down after… Continue reading →